ReviewWorld journal of oncology2022
Advances in the Treatment of Mucoepidermoid Carcinoma.
Review in World journal of oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Clinicopathological Analysis of Salivary Glands Warthin-like Mucoepidermoid Carcinoma: A Systematic Review.Head and neck pathology · 2025Pooled it
- Quercetin as a Therapeutic Agent for Oral Cancer: Current Evidence and Future Directions.Asia-Pacific journal of clinical oncology · 2026Review
- Clinicopathologic characteristics and prognostic factors of mucoepidermoid carcinoma: a 20-year real-world cohort study.ESMO real world data and digital oncology · 2026Article
- Parotid mucoepidermoid carcinoma presenting as a cutaneous mass.JAAD case reports · 2026Article
- Ultrasonic viscoelastic imaging: a tool for parotid gland tumor differentiation.European radiology · 2026Article
- Thrombospondin-1 triggers calreticulin expression in human mucoepidermoid carcinoma MC-3 cells via the PERK/CHOP pathway.Oncology letters · 2026Article
- Review
- Prognostic Role of Unconventional Tumor Site of Origin in Mucoepidermoid Carcinoma: A Comprehensive Analysis Using the SEER Database.Head and neck pathology · 2026Article
- Case Report: Treatment of an unresectable mucoepidermoid carcinoma with osimertinib.Frontiers in oncology · 2026Article
- Operculectomy Preceding a Mucoepidermoid Carcinoma Development: Case Report.Case reports in dentistry · 2026Article
- Article
- Clinical features and prognostic factors of salivary adenoid cystic and mucoepidermoid carcinomas.Medicine · 2025Article
- Mucoepidermoid carcinoma of unknown primary in the head and neck: a case report and review of the literature.The Journal of laryngology and otology · 2025Review
- Intermediate Grade Salivary Gland Mucoepidermoid Carcinoma: Is Neck Dissection Indicated?Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2025Article
- Intraosseous Mucoepidermoid Carcinoma-Case Series of a Rare but Recurring Entity.Indian journal of surgical oncology · 2025Article
- CD44 and EPCAM expression in pleomorphic adenoma and mucoepidermoid carcinoma: An immunohistochemical method.Dental research journal · 2025Article
- The Molecular Biology of MEC Salivary Gland Tumors.Annals of otolaryngology and rhinology · 2025Article
- MINOCA as the result of coronary artery aneurysm thrombosis.The Journal of international medical research · 2024Article
- Parotid Gland Tumors: Molecular Diagnostic Approaches.International journal of molecular sciences · 2024Review
- Current Developments in Diagnosis of Salivary Gland Tumors: From Structure to Artificial Intelligence.Life (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mucoepidermoid carcinoma (MEC) represents 10-15% of salivary neoplasms. Due to their low incidence, it is challenging to conduct clinical trials and develop treatment guidelines. Although surgery is the most common approach for a resectable tumor, various treatment options such as chemotherapy, radiotherapy, and immunotherapy have been investigated. There is a need to implement a standardized treatment protocol to effectively manage MEC as it is a common histological subtype. Furthermore, it has become essential to assess chromosomal and genetic abnormalities recently identified with MEC, including alterations of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.